Cargando…

A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia

PI3Kδ (idelalisib) and BTK (ibrutinib) inhibitors have demonstrated significant clinical activity in chronic lymphocytic leukemia (CLL) interfering with the cross-talk between CLL cells and the lymph node microenviroment, yet their mechanism of action remains to be fully elucidated. Here, we develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Primo, Daniel, Scarfò, Lydia, Xochelli, Aliki, Mattsson, Mattias, Ranghetti, Pamela, Espinosa, Ana Belén, Robles, Alicia, Gorrochategui, Julian, Martínez-López, Joaquín, de la Serna, Javier, González, Marcos, Gil, Alberto Chaparro, Anguita, Eduardo, Iraheta, Sandra, Munugalavadla, Veerendra, Quéva, Christophe, Tannheimer, Stacey, Rosenquist, Richard, Stamatopoulos, Kostas, Ballesteros, Joan, Ghia, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995261/
https://www.ncbi.nlm.nih.gov/pubmed/29899839
http://dx.doi.org/10.18632/oncotarget.25419